# The Surprising Reason This Biotech Plummeted 69%

> **Newsylist Open Intelligence Dossier** · First detected: 2026-08-17 15:29 UTC · Category: Business · Sources: 10 · Current Velocity: 9.49

## Executive Summary
EyePoint Pharmaceuticals shares cratered following a late-stage trial setback for its flagship eye disease drug.

## Intelligence Brief
EyePoint Pharmaceuticals investors faced steep losses as shares plummeted significantly following trial results. The Phase 3 LUGANO trial for the drug DURAVYU, targeting the age-related eye disease wet AMD, missed its primary endpoint. Financial analysts and market observers quickly reacted to the trial failure.


Cantor Fitzgerald downgraded EyePoint Pharmaceuticals to neutral. Reports from Barron's, Yahoo Finance, MarketBeat, and Investor's Business Daily noted that the stock was on track to hit 16-month lows, cratering between 69 percent and 71 percent in market value. Despite missing the primary endpoint, secondary data indicated that DURAVYU reduced the treatment burden.


Coverage does not yet specify the company's upcoming regulatory or clinical steps following the setback.

## Verified Facts & Key Claims
### What caused EyePoint stock to plummet?
The stock plummeted after the Phase 3 LUGANO trial for DURAVYU missed its primary endpoint.

### What disease was the trial targeting?
The trial targeted wet age-related macular degeneration (wet AMD).

### How did financial institutions react?
Cantor Fitzgerald downgraded EyePoint Pharmaceuticals to neutral following the trial failure.

## Key People, Organizations & Locations
Surprising Reason This Biotech Plummeted, EyePoint, EyePoint DURAVYU Phase, LUGANO Trial Misses Primary Endpoint, Secondary Data Show Reduced Treatment Burden, Cantor Fitzgerald Downgrades Eyepoint Pharmaceuticals, Neutral, EyePoint's DURAVYU Cut Treatment Burden

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| Yahoo Finance | Why Did EYPT, STLA, ENVX Stocks Plunge To 52-Week Lows Today? | 2026-08-17 20:33 | [Source Link](https://news.google.com/rss/articles/CBMikAFBVV95cUxNY0NOY1RkWkszRW4zOGpLdHN1Qy1HRHR4Y2Jucnp1TkpVdzhCVU5UdHduU2N2VTFLNk1tTmRzWEVENnYxZjFrNmQ2VmpUck5Qc0hCLW55cU1RSEhLUmczMWpCd0w0ek9KTW9IYzdRZEtHRzl1a1BSNFBkSHJtNEJkY0s3Smc0c3Bqb1YtS0lHV3E?oc=5) |
| BioSpace | EyePoint’s Phase 3 fail sends stock spiraling amid next-gen AMD race | 2026-08-17 18:07 | [Source Link](https://news.google.com/rss/articles/CBMirgFBVV95cUxNbUxmZ1lwVnVHQTB1Q1pEUmhQMzJtZVZ5SWJlRzkybWJQVHFlRTk5MzRnY3ZDS0VETl9FQjNwYm5kc1JxLTlIZHFlWk1sS002M0FieUZaZjFCaVV0ZjNDNFZLYmJSbHd2dHc5QUxQc29HWEdUa09sZ2N5aDNNUUJONkhVSDBpSFJmTndzSHlCQ1RrYUdKR1VHcGpYOW4zb1AzWXBwQTNPY0wtdDJLR2c?oc=5) |
| fiercepharma.com | EyePoint shares plummet after phase 3 stumble for AMD drug-device combo Duravyu | 2026-08-17 18:07 | [Source Link](https://news.google.com/rss/articles/CBMirwFBVV95cUxNOWYzSnd1bk5ZSHJoaFRibFB4b3hLNU9ONVRBV3VKWE5hckpVVXdZRDZWREVFTVB0NXd1b3o5LXB6b29jR0Vuckc0elRJYXJqYWZ6a3VzbWhIcC1FZGpXNnJGV09LMXgxYzgxeDZ0U0ZKTFdRMTcyTVo0cDFZWjJGemN2ZVAtd3pKeU9YTEQ3NzVQcENaV1dpdDd0YkctcWc4aUY3ZEllcEhLLVhMeEZR?oc=5) |
| STAT | Eyepoint study results for vision treatment disappoint, but company still sees promise | 2026-08-17 18:07 | [Source Link](https://news.google.com/rss/articles/CBMidkFVX3lxTE93Q05QU20zcEpoU2RtX3NUQTltUFRSREJZX2gzTW1GVUFCVGZHSThFNlNoZXpERXkzYlh1Q1RQWXB6a0xXaXVrTmNPUGhyWU1MVGMzeWQtMDZ2SS1YZ21qdk9wTWN0Q3NRUXhBY245QV9hTGdOZmc?oc=5) |
| Yahoo Finance | EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD | 2026-08-17 13:37 | [Source Link](https://news.google.com/rss/articles/CBMioAFBVV95cUxNb0NhWWUwSml4ZHplaHZOVEI2UlpDeDhzc0lDZlFObkFCbmxDZFpFcW5kWUVVU0IwdTNzWjRqSV9wMU5QWG5NQ0hyenpSd0tlZ3pqemFrZGFXdG15ZG1ydlRiOTRsaU9yVG82ejItQi1PaDdmQlk0RFVWbFFXSWszbUx1UTdCd24yZFRZUHYxSzlWTFdBdGVITVJuVjllX0Np?oc=5) |
| Reuters | EyePoint's drug for age-related eye disease fails late-stage trial, shares tank | 2026-08-17 13:37 | [Source Link](https://news.google.com/rss/articles/CBMiwgFBVV95cUxPS0pNQnFBWENtcFppVm1lNnZ1RnVRV3pYT2luc2RnMk9QYVFrb1g5VkVQNXlDbXdRMnR2Yk54Ym9mX0xiSnJPbDI1T29GNTVNeGFuUFFzZDZ4OXQxcGo2QlVkRU1velpHUTQ4WGdrcGdaTHlmMkUxVWlQMVBkWFNmVFdBMzBzaGYwZlQ0MFF5ak1qWC1IOGxtN2RQdGhhVkFBWFJfbDZZMEFIbF9FRVVjSG83NWdsTzFmVF9wMGtySTFCQQ?oc=5) |
| Yahoo Finance | EyePoint DURAVYU Phase 3 LUGANO Trial Misses Primary Endpoint as Secondary Data Show Reduced Treatment Burden | 2026-08-17 13:37 | [Source Link](https://news.google.com/rss/articles/CBMilwFBVV95cUxNelRVYXRSXzBhTmZNVkRWSVNEb09TRHJtOUM3ZHlkaFZqMWNUTWJjdWlpcUJmdEdMWnBGNURNOUlOY1ozWmhYYWRnek1TNnBzNHFVU2EtNUpxcGQ4ejlIYlVsMFVWM2h1NjRjNU5mdjgwQldCTnZrQUlOMVRpQTY0VHVwOXBKa2NvMG96RzFkTHY1UFlZcmk0?oc=5) |
| MarketBeat | Cantor Fitzgerald Downgrades Eyepoint Pharmaceuticals (NASDAQ:EYPT) to Neutral | 2026-08-17 13:37 | [Source Link](https://news.google.com/rss/articles/CBMiyAFBVV95cUxONW5KUDRFN01xZE9VNlM4SHY4SFFId3NGZTdsVzl1U0NuR3pkRjg3TDR4alNxOWdvZUpOd1poMklzUWFFaXZPVzdkX0NsQmlrTWhQMVJnZG9ONzAwYkcxaEU1ZmtGUHJ0bWJ3TXRzeGs2ZU5CMWRJcXJXczZqUUczZWkzZWFTVGJYcXJHLV9KdllNeDNEVmM2Sm4yaVUza2I1NjM1WExNWF8ybDVJbGNCNjB0alc1WHdtQlJ5MEhhT3NEZGx3ak56cA?oc=5) |
| Stock Titan | EyePoint's DURAVYU Cut Treatment Burden 42%—What It Missed | 2026-08-17 13:37 | [Source Link](https://news.google.com/rss/articles/CBMitwFBVV95cUxQamlkSnJobGh5TWpJdmtnTkdVcndJUTk5WlJjMm9OODU3ck4yWF96MUkyZV9YSjZmS3ZGSWRpYVVCNmR4Qmd0QWJNNGxJc0ppLTRRTnBpR3J3UHktdUh4dEUwdWF2YzZiYzFEX0MtNk1ERXc2bThfYU0tZWVTcFl4Q2duQktTQTdNckxjS1VPTEV2YmN2Z2FSeDAyWTJTeS1TRHdzaU1HVFRtRGpTMlphaFh5Ty1NZkU?oc=5) |
| barrons.com | EyePoint Stock Craters 71% After Drug Trial Failure. It May Be an Overreaction. | 2026-08-17 13:37 | [Source Link](https://news.google.com/rss/articles/CBMiiwFBVV95cUxOSWtIdk9CdVMxQ0k3WWs2eV9vZUNpaDEyS0xDSXJ4UUp6dUdtZGRERDV0QVZrdGZpS3ptcnZBNzhQdkJ5RERadElHZGx1TnJIbWExN0JDTFFKUjBodFpJYUhtNEVwRWdaNE9HU1BsLVFaalhvemp2V2xwSEFXSENZUkVtS2xsdUFIVmtV?oc=5) |
| finance.yahoo.com | EYPT Stock On Track To Hit 16-Month Lows After Wet AMD Trial Setback | 2026-08-17 13:37 | [Source Link](https://news.google.com/rss/articles/CBMikgFBVV95cUxPaXEycmpYWHB5ckpRUjhNeWtEZFJrVHVBVEcyLVFQOVlOQWcxVjVQakt0dWtad2pDak9yQ3ZLcmVJdTVwUXJTUXl2TTZ4R2RDaGNZNVFlTEZFdnZMZW1tOFJTVTFULXRQYUlZUTNNOXpsQU43d043c1VFWTVaaVM0MVVrWVFMRW9haG9XTXBXRk1zQQ?oc=5) |
| Investor's Business Daily | The Surprising Reason This Biotech Plummeted 69% | 2026-08-17 13:37 | [Source Link](https://news.google.com/rss/articles/CBMikAFBVV95cUxPanNZVWtvQnJDbFpLbGw4R25TZ3AwVDhiVnFvTEg3NDFjbi0zOFo0MkhkaXRCa2I2WkxIay03Zk5wSjFFTzBWT3FFUzBkWlFNeWtTeHJFTjhJUWc4ek5aMjF1bWVBcWpoaXMxeUVGUnR1aVItTFlXcmVUR3B5NW5MV0hPNk92dUJyYnVqcEdBSE0?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-08-17/the-surprising-reason-this-biotech-plummeted-69*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*